Search Within

Maria Michelle Rubinstein

  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (5)
Groups
  1. Department of Medicine (14)
  2. GDMT, Medicine (14)
  3. Gynecologic Medicine Service (14)
  4. Gynecology Disease Management Team (14)
  5. Hematologic Malignancies, Division of (14)
  6. Solid Tumor Oncology Division (14)

More Groups

People
  1. Roisin O'Cearbhaill (12)
  2. Vicky Makker (12)
  3. Carol Aghajanian (11)
  4. Rachel Grisham (10)
  5. Martee Hensley (9)
  6. Claire Friedman (8)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (1)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. Gynecologic Oncology (5)
  2. Journal of Clinical Oncology (2)
  3. Cancer (1)
  4. Clinical Case Reports (1)
  5. Gynecologic Oncology Reports (1)
  6. International Journal of Gynecological Cancer (1)

More Publications

Publishers
  1. Elsevier Inc. (5)
  2. American Society of Clinical Oncology (2)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Biomed Central Ltd (1)
  6. Elsevier B.V. (1)

More Publishers

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate
    Journal Article

    Johannet, P.; Flint, M.; Chui, M. H.; Konner, J.; Friedman, C.; Green, A. K.; Guo, R.; Hensley, M. L.; Kyi, C.; Liu, Y.; more...
    Gynecologic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer
    Meeting Abstract

    Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcomas
    Journal Article

    Sia, T. Y.; Gordhandas, S. B.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M. L.; Rubinstein, M.; Makker, V.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
    Journal Article

    Rubinstein, M. M.; Grisham, R. N.; Cadoo, K.; Kyi, C.; Tew, W. P.; Friedman, C. F.; O'Cearbhaill, R. E.; Zamarin, D.; Zhou, Q.; Iasonos, A.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save